These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26340515)

  • 1. Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.
    Leenaerts D; Bosmans JM; van der Veken P; Sim Y; Lambeir AM; Hendriks D
    J Thromb Haemost; 2015 Dec; 13(12):2227-32. PubMed ID: 26340515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.
    Leenaerts D; Aernouts J; Van Der Veken P; Sim Y; Lambeir AM; Hendriks D
    Thromb Haemost; 2017 Jul; 117(8):1498-1508. PubMed ID: 28692110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
    Claesen K; Mertens JC; Leenaerts D; Hendriks D
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis.
    Mertens JC; Claesen K; Leenaerts D; Sim Y; Lambeir AM; Hendriks D
    J Thromb Haemost; 2019 Jun; 17(6):878-884. PubMed ID: 30887647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study.
    Claesen K; Mertens JC; Basir S; De Belder S; Maes J; Bosmans J; Stoffelen H; De Meester I; Hendriks D
    Clin Ther; 2021 May; 43(5):908-916. PubMed ID: 33910760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction.
    Mertens JC; Leenaerts D; Brouns R; Engelborghs S; Ieven M; De Deyn PP; Lambeir AM; Hendriks D
    J Thromb Haemost; 2018 Feb; 16(2):342-348. PubMed ID: 29194929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ProCPU Is Expressed by (Primary) Human Monocytes and Macrophages and Expression Differs between States of Differentiation and Activation.
    Claesen K; De Loose J; Van Wielendaele P; De Bruyn E; Sim Y; Thys S; De Meester I; Hendriks D
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboxypeptidase U (TAFIa) Is Rapidly Activated and Deactivated Following Thrombolysis and Thrombectomy in Stroke Patients.
    Mertens JC; Blanc-Guillemaud V; Claesen K; Cardona P; Hendriks D; Tyl B; Molina CA
    Transl Stroke Res; 2022 Dec; 13(6):959-969. PubMed ID: 34796454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.
    Heylen E; Willemse J; Hendriks D
    Front Biosci (Landmark Ed); 2011 Jun; 16(7):2427-50. PubMed ID: 21622187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models.
    Leenaerts D; Loyau S; Mertens JC; Boisseau W; Michel JB; Lambeir AM; Jandrot-Perrus M; Hendriks D
    J Thromb Haemost; 2018 Oct; 16(10):2057-2069. PubMed ID: 30053349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients with SARS-CoV-2 Infection Could Contribute to COVID-19 Hypofibrinolytic State and Disease Severity Prognosis.
    Claesen K; Sim Y; Bracke A; De Bruyn M; De Hert E; Vliegen G; Hotterbeekx A; Vujkovic A; van Petersen L; De Winter FHR; Brosius I; Theunissen C; van Ierssel S; van Frankenhuijsen M; Vlieghe E; Vercauteren K; Kumar-Singh S; De Meester I; Hendriks D
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growing thrombi release increased levels of CD235a(+) microparticles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients.
    Suades R; Padró T; Vilahur G; Martin-Yuste V; Sabaté M; Sans-Roselló J; Sionis A; Badimon L
    J Thromb Haemost; 2015 Oct; 13(10):1776-86. PubMed ID: 26239059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
    Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D
    Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
    Mertens JC; Boisseau W; Leenaerts D; Di Meglio L; Loyau S; Lambeir AM; Ducroux C; Jandrot-Perrus M; Michel JB; Mazighi M; Hendriks D; Desilles JP
    J Thromb Haemost; 2020 Dec; 18(12):3325-3335. PubMed ID: 32869423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease.
    Silveira A; Schatteman K; Goossens F; Moor E; Scharpé S; Strömqvist M; Hendriks D; Hamsten A
    Thromb Haemost; 2000 Sep; 84(3):364-8. PubMed ID: 11019956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis.
    Knecht W; Willemse J; Stenhamre H; Andersson M; Berntsson P; Furebring C; Harrysson A; Hager AC; Wissing BM; Hendriks D; Cronet P
    FEBS J; 2006 Feb; 273(4):778-92. PubMed ID: 16441664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
    Bridge KI; Bollen L; Zhong J; Hesketh M; Macrae FL; Johnson A; Philippou H; Scott DJ; Gils A; Ariёns RAS
    J Thromb Haemost; 2017 Nov; 15(11):2218-2225. PubMed ID: 28834317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients.
    Brouns R; Heylen E; Sheorajpanday R; Willemse JL; Kunnen J; De Surgeloose D; Hendriks DF; De Deyn PP
    Clin Neurol Neurosurg; 2009 Feb; 111(2):165-70. PubMed ID: 18980797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP; Blombäck M
    Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma.
    Leurs J; Wissing BM; Nerme V; Schatteman K; Björquist P; Hendriks D
    Thromb Haemost; 2003 Feb; 89(2):264-71. PubMed ID: 12574805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.